other material
confidence high
sentiment positive
materiality 0.85
CG Oncology reports 42.3% 24-month CR rate in BOND-003; 97.3% progression-free at 24 mo
CG Oncology, Inc.
- BOND-003 Cohort C: 75.5% complete response (CR) at any time; 42.3% 24-month CR by K-M estimate.
- Median duration of response 28 months; 58.3% of responders maintained CR at 24 months by K-M.
- 97.3% of patients free from progression to muscle-invasive bladder cancer at 24 months; 91.6% cystectomy-free.
- No Grade 3+ treatment-related adverse events or deaths; median resolution of any TRAE was one day.
- Cohort P (Ta/T1 without CIS): 90.5% high-grade recurrence-free survival at 3 and 9 months (n=24).